Time since SARS-CoV-2 infection and humoral immune response following BNT162b2 mRNA vaccination

EBioMedicine

Marije K. Bomers¹  A.H. Ayesha Lavell²  Meliawati Poniman³  Judith A. Burger⁴  Brent Appelman⁴  Marit J. van Gils⁴  Marleen A. Slim⁴  Yvo M. Smulders⁵  Lonneke A. van Vught⁶  Rogier W. Sanders⁷  Michiel Schinkel⁷  Melissa Oomen⁸  Khadija Tejjani⁸  W. Joost Wiersinga⁸  Alexander P.J. Vlaar⁸  Jonne J. Sikkens⁸  Karlijn van der Straten⁸ 

[1] Department of Intensive Care Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands;Department of Internal Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands;Department of Internal Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, the Netherlands;Center for Experimental and Molecular Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands;Department of Intensive Care Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands;Department of Internal Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands;Department of Internal Medicine, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, the Netherlands;Department of Medical Microbiology, Amsterdam UMC, Amsterdam Institute for Infection and Immunity, University of Amsterdam, Meibergdreef 9, Amsterdam 1105 AZ, the Netherlands;

关键词: Vaccine;    BNT162b2;    SARS-CoV-2;    COVID-19;    Humoral immune response;    Neutralisation;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: To optimise the use of available SARS-CoV-2 vaccines, some advocate delaying second vaccination for individuals infected within six months. We studied whether post-vaccination immune response is equally potent in individuals infected over six months prior to vaccination. Methods: We tested serum IgG binding to SARS-CoV-2 spike protein and neutralising capacity in 110 healthcare workers, before and after both BNT162b2 messenger RNA (mRNA) vaccinations. We compared outcomes between participants with more recent infection (n = 18, median two months, IQR 2-3), with infection-vaccination interval over six months (n = 19, median nine months, IQR 9-10), and to those not previously infected (n = 73). Findings: Both recently and earlier infected participants showed comparable humoral immune responses after a single mRNA vaccination, while exceeding those of previously uninfected persons after two vaccinations with 2.5 fold (p = 0.003) and 3.4 fold (p < 0.001) for binding antibody levels, and 6.4 and 7.2 fold for neutralisation titres, respectively (both p < 0.001). The second vaccine dose yielded no further substantial improvement of the humoral response in the previously infected participants (0.97 fold, p = 0.92), while it was associated with a 4 fold increase in antibody binding levels and 18 fold increase in neutralisation titres in previously uninfected participants (both p < 0.001). Adjustment for potential confounding of sex and age did not affect these findings. Interpretation: Delaying the second vaccination in individuals infected up to ten months prior may constitute a more efficient use of limited vaccine supplies. Funding: Netherlands Organization for Health Research and Development ZonMw; Corona Research Fund Amsterdam UMC; Bill & Melinda Gates Foundation.

【 授权许可】

Unknown